These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27628460)

  • 21. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
    Ivandic B; Zorn M
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.
    Rice L; Hursting MJ; Baillie GM; McCollum DA
    J Clin Pharmacol; 2007 Aug; 47(8):1028-34. PubMed ID: 17525167
    [No Abstract]   [Full Text] [Related]  

  • 25. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions.
    Escolar G; Bozzo J; Maragall S
    Drugs Today (Barc); 2006 Apr; 42(4):223-36. PubMed ID: 16703119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful recovery after an overdose of argatroban.
    Yee AJ; Kuter DJ
    Ann Pharmacother; 2006 Feb; 40(2):336-9. PubMed ID: 16449547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental and clinical results with the thrombin inhibitor Argatroban].
    Breddin HK
    Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time.
    Engström M; Rundgren M; Schött U
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):86-91. PubMed ID: 19719819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
    Van Cott EM; Roberts AJ; Dager WE
    Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of the direct thrombin inhibitor argatroban.
    Walenga JM
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():9-14. PubMed ID: 12811006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Argatroban in extracorporeal membrane oxygenation.
    Beiderlinden M; Treschan T; Görlinger K; Peters J
    Artif Organs; 2007 Jun; 31(6):461-5. PubMed ID: 17537058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
    Ansara AJ; Arif S; Warhurst RD
    Ann Pharmacother; 2009 Jan; 43(1):9-18. PubMed ID: 19126826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.
    Begelman SM; Baghdasarian SB; Singh IM; Militello MA; Hursting MJ; Bartholomew JR
    J Intensive Care Med; 2008; 23(5):313-20. PubMed ID: 18701526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices.
    Pappalardo F; Scandroglio AM; Potapov E; Stepanenko A; Maj G; Krabatsch T; Zangrillo A; Koster A; Hetzer R
    Minerva Anestesiol; 2012 Mar; 78(3):330-5. PubMed ID: 22357371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
    Pendleton R; Wheeler MM; Rodgers GM
    Ann Pharmacother; 2006 May; 40(5):972-6. PubMed ID: 16569813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.